204 related articles for article (PubMed ID: 15294457)
41. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.
Mizushima H; Takanaka K; Abe K; Fukazawa I; Ishizuka H
Xenobiotica; 2007 Jan; 37(1):59-73. PubMed ID: 17178634
[TBL] [Abstract][Full Text] [Related]
42. In vitro metabolism of a new oxazolidinedione hypoglycemic agent utilizing liver microsomes and recombinant human cytochrome P450 enzymes.
Agrawal AK; Hop CE; Pang J; Silva Elipe MV; Desai RC; Leung KH; Franklin RB
J Pharm Biomed Anal; 2005 Feb; 37(2):351-8. PubMed ID: 15708677
[TBL] [Abstract][Full Text] [Related]
43. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.
Kreth K; Kovar K; Schwab M; Zanger UM
Biochem Pharmacol; 2000 Jun; 59(12):1563-71. PubMed ID: 10799653
[TBL] [Abstract][Full Text] [Related]
44. Kinetic deuterium isotope effects for 7-alkoxycoumarin O-dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes. Rate-limiting C-H bond breaking in cytochrome P450 1A2 substrate oxidation.
Kim KH; Isin EM; Yun CH; Kim DH; Guengerich FP
FEBS J; 2006 May; 273(10):2223-31. PubMed ID: 16649998
[TBL] [Abstract][Full Text] [Related]
45. In vivo and in vitro inhibition of the metabolism of N-alkyl-substituted amphetamines in rat by ferrocenylisopropylamine.
Vree TB; Henderson PT; von Rossum JM; Doukas PH
Xenobiotica; 1973 Jan; 3(1):23-35. PubMed ID: 4701301
[No Abstract] [Full Text] [Related]
46. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.
Rowland K; Ellis SW; Lennard MS; Tucker GT
Br J Clin Pharmacol; 1996 Sep; 42(3):390-3. PubMed ID: 8877032
[TBL] [Abstract][Full Text] [Related]
47. The importance of heterogeneous nuclear ribonucleoprotein K on cytochrome P450 2D2 gene regulation: its binding is reduced in Dark Agouti rats.
Sakai N; Sakamoto KQ; Fujita S; Ishizuka M
Drug Metab Dispos; 2009 Aug; 37(8):1703-10. PubMed ID: 19420131
[TBL] [Abstract][Full Text] [Related]
48. [Mechanism of mono-hydroxylation of daidzein in human liver microsomes].
Peng WX; Li HD; Zhou HH
Yao Xue Xue Bao; 2004 Nov; 39(11):892-6. PubMed ID: 15696928
[TBL] [Abstract][Full Text] [Related]
49. Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib.
Xu HY; Xie ZY; Zhang P; Sun J; Chu FM; Guo ZR; Zhong DF
Acta Pharmacol Sin; 2006 Mar; 27(3):372-80. PubMed ID: 16490176
[TBL] [Abstract][Full Text] [Related]
50. Dopamine formation from tyramine by CYP2D6.
Hiroi T; Imaoka S; Funae Y
Biochem Biophys Res Commun; 1998 Aug; 249(3):838-43. PubMed ID: 9731223
[TBL] [Abstract][Full Text] [Related]
51. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step.
Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
Xenobiotica; 2004 Feb; 34(2):179-92. PubMed ID: 14985146
[TBL] [Abstract][Full Text] [Related]
52. A real-time fluorescence assay for measuring N-dealkylation.
Mayer RT; Dolence EK; Mayer GE
Drug Metab Dispos; 2007 Jan; 35(1):103-9. PubMed ID: 17035601
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms.
Daniel WA; Haduch A; Wójcikowski J
Eur Neuropsychopharmacol; 2005 Jan; 15(1):103-10. PubMed ID: 15572279
[TBL] [Abstract][Full Text] [Related]
54. Metabolism of trimipramine in vitro by human CYP2D6 isozyme.
Bolaji OO; Coutts RT; Baker GB
Res Commun Chem Pathol Pharmacol; 1993 Oct; 82(1):111-20. PubMed ID: 8272570
[TBL] [Abstract][Full Text] [Related]
55. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
56. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.
Picard N; Cresteil T; Djebli N; Marquet P
Drug Metab Dispos; 2005 May; 33(5):689-95. PubMed ID: 15743975
[TBL] [Abstract][Full Text] [Related]
57. Evidence for CYP2D1-mediated primary and secondary O-dealkylation of ethylmorphine and codeine in rat liver microsomes.
Xu BQ; Aasmundstad TA; Christophersen AS; Mørland J; Bjørneboe A
Biochem Pharmacol; 1997 Feb; 53(4):603-9. PubMed ID: 9105413
[TBL] [Abstract][Full Text] [Related]
58. Activation energies of alpha-C-oxidation and N-oxidation of N-alkyl-substituted amphetamines by rat liver microsomes. Stereochemistry and deuterium isotope effects.
Henderson PT; Vree TB; van Ginneken CA; van Rossum JM
Xenobiotica; 1974 Feb; 4(2):121-30. PubMed ID: 4828797
[No Abstract] [Full Text] [Related]
59. Regiochemistry and enantioselectivity in the oxidative N-dealkylation of verapamil.
Nelson WL; Olsen LD
Drug Metab Dispos; 1988; 16(6):834-41. PubMed ID: 2907462
[TBL] [Abstract][Full Text] [Related]
60. Chiral gas chromatographic assay with flame ionization detection for amphetamine enantiomers in microsomal incubates.
Zeng S; Zhang L; Chen YZ
Biomed Chromatogr; 1999 Feb; 13(1):33-6. PubMed ID: 10191941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
